January 2010 Issue of MMM
When we set out to find our five All-Star teams for 2010, we were a little concerned that it might turn into an exercise for ...
Perhaps no large pharmaceutical company is so well positioned to survive the approaching patent cliff as Novartis. And it's no accident that the Swiss giant ...
Euro RSCG Life last year increased revenue by double digits, won a number of major AOR assignments and hired more than 150 people. Add to ...
AstraZeneca's Symbicort, the second-to-market ICS/LABA combo behind GlaxoSmithKline's Advair, faced an uphill battle on its launch in June 2007, squaring off against a firmly entrenched ...
Shire is in an enviable place with its ADHD franchise. About three years ago, the specialty biopharma company received US approval for Vyvanse in children, ...
HealthiNation, a producer and purveyor of independent health video, is pulling in consumers with high-quality content, and an increasing number of pharma advertisers with a ...
As online-advertising standards get closer to reality, agencies and industry also need to learn to work together to orchestrate tactics such as social networks and ...
Over the past decade, numerous changes have impacted the healthcare market and driven marketplace volatility. Among them, managed care continues to influence brand success, and ...
In mid-November, the FDA came out with a strong warning against using Prilosec (omeprazole) in combination with the anti-clotting drug Plavix (clopidogrel).
The nature and amount of press coverage is often a key factor in assessing how clinical trial results impact a product's prescription trends.
King's launch of Embeda, a pain drug containing morphine, demonstrates that even supposedly abuse-resistant narcotic products need to take a careful approach in their marketing.
Sanofi-Aventis said it would lay off 750, or nearly 12%, of its US sales reps, as the firm retrenches in the face of generic exposure ...
Featuring news about Cegedim Dendrite, Eisai, Celgene and Gloucester Pharmaceuticals
Med Ed Report
A recent Institute of Medicine (IOM) report focused on reforming CME offers a new catalyst for change: a public-private institute that would alter the way ...
GlaxoSmithKline said it paid nearly $15 million in fees in the second quarter to US healthcare professionals for speaking and consulting services.
Featuring news about the AMA, American Cancer Society, the Canadian Medical Association, Pri-Med and Northwestern University Feinberg School of Medicine
The MPR database of 4,000 drug products is now accessible via the iPhone mobile device.
Authors writing for most of the top medical journals are required to disclose relationships with industry or other organizations that could pose conflicts of interest, ...
Featuring news about Quadrant HealthCom, Dowden Health Media, Lebhar-Friedman, Elsevier, Embase, Harvard and Johns Hopkins
For all the talk about Twitter, Facebook and Sermo as marketing channels of the future, will social networks ever provide a viable platform for promoting ...
FDA announced a collaboration with Everyday Health aimed at pushing FDA information on health topics out to the health portal's 30 million or so monthly ...
CBS Interactive said it would jettison third-party advertising networks and instead handle ad sales for its properties, including CBS.com, CBSNews.com, CNET.com and TV.com, in-house.
Chantix became the latest pharmaceutical advertised on the HealthiNation health-video network, with the brand's banner ad running beneath clips on quitting smoking and losing weight.
Featuring news about Microsoft, Sentillion, comScore, AOL, Google and WebMD
One of the biggest problems for DTC marketers is that there is no packaging for consumers to bond with (remember the "eighth P" of the ...
Sanofi-Aventis launched an iPhone application aimed at helping diabetics count calories on the go.
Consumers tend to block out risk info in TV and print ads for prescription drugs—particularly those over age 55—according to a study by ORC Guideline.
GlaxoSmithKline Consumer Healthcare is taking an irreverent tone with its latest ads for Nicorette, featuring the tagline "Makes Quitting Suck Less."
Pfizer boosted ad spend 12% for the first nine months of 2009 over the same period in 2008, even as ad spend for the sector ...
Featuring news about Johnson & Johnson's McNeil Consumer, Deutsch and GlaxoSmithKline
New Jersey's Division of Consumer Affairs recommended tight controls on data-mining, among other limits designed to prevent conflicts of interest in medicine. But health information ...
Pharma's increased investment in co-pay card programs has led research firm TargetRx to launch a product offering more insight into their adoption and use.
Medical advertising pioneer Frank J. Corbett passed away in December.
Saatchi & Saatchi Wellness EVP director of client service Ned Russell was promoted to EVP managing director after Jim Joseph left the firm to join ...
Featuring news about Novartis, Harrison & Star, Partners + simons, LehmanMillet, Myriad Genetics, Cadient Interactive and Hatch Consulting
Having held the Super Bowl of Part 15 hearings on social media, the big question is, what's the FDA's next move?
"Reducing preventable harm from prescription and OTC medication use is an FDA priority," according to FDA commissioner Margaret Hamburg.
When Google launched Sidewiki in September, pharma professionals were up in arms over managing the fallout.
The changes in mammography guidelines by the US Preventative Systems Task Force (USPSTF) announced in late November were not surprisingly met with great confusion, frustration ...
American consumers are used to warranties. If you buy a TV set and it stops working within a specified time, you can ask for a ...
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- FCB Health's Rich Levy on HIV/AIDS Campaigns that Fight Stigma
- Five things for pharma marketers to know: Monday, October 24, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Sunovion hires former BI exec as VP of marketing
- Merck's Keytruda wins approval in first-line lung cancer
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Top 25 neurology products, based on 2016 sales forecasts